Nathalia Grigorovski1, Evandro Lucena2, Clarissa Mattosinho2, Andreu Parareda3, Sima Ferman1, Jaume Catalá4, Guillermo Chantada3. 1. Department of Pediatric Oncology, Instituto Nacional de Câncer, Rio de Janeiro 20230-130, Brazil. 2. Ophthalmic Oncology Service, Instituto Nacional de Câncer, Rio de Janeiro 20230-130, Brazil. 3. Oncology Service, Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona 208950, Spain. 4. Ophthalmology Service, Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona 208950, Spain.
Abstract
AIM: To obtain baseline knowledge about the current use of intra-arterial chemotherapy (SSOAIC) in centers worldwide. METHODS: A survey including questions about the use of SSOAIC was emailed to retinoblastoma experts. RESULTS: Seventy-nine (response rate 69.9%) doctors from 63 centers in 35 countries responded. Thirty-one centers from 19 countries use SSOAIC. Twelve performed more than 50 procedures. Melphalan is the most commonly used drug but 15 centers use more than one drug. First line therapy for advanced unilateral disease is the most common use of SSOAIC (74.2%). Centers with larger experience (>50 applications) were less likely using melphalan alone (P=0.06) and significantly more likely using SSOAIC in more situations such as second line in preference to radiotherapy P=0.05. Nineteen (61.2%) stated that SSOAIC improved their results and 21 (77.8%) reported less toxicity compared to other treatments. Three centers reported that SSOAIC did not improve their results. There were regional variations in the use of SSOAIC which is used more frequently as secondary treatment in Europe compared to the USA and Japan. Ten centers identified cost is the major limiting factor for SSOAIC. CONCLUSION: SSOAIC is used in an increasing number of centers worldwide with regional variations. Centers with more experience in SSOAIC use it in more situations including other drugs than melphalan. The majority of the centers using this technique reported improved results and few complications.
AIM: To obtain baseline knowledge about the current use of intra-arterial chemotherapy (SSOAIC) in centers worldwide. METHODS: A survey including questions about the use of SSOAIC was emailed to retinoblastoma experts. RESULTS: Seventy-nine (response rate 69.9%) doctors from 63 centers in 35 countries responded. Thirty-one centers from 19 countries use SSOAIC. Twelve performed more than 50 procedures. Melphalan is the most commonly used drug but 15 centers use more than one drug. First line therapy for advanced unilateral disease is the most common use of SSOAIC (74.2%). Centers with larger experience (>50 applications) were less likely using melphalan alone (P=0.06) and significantly more likely using SSOAIC in more situations such as second line in preference to radiotherapy P=0.05. Nineteen (61.2%) stated that SSOAIC improved their results and 21 (77.8%) reported less toxicity compared to other treatments. Three centers reported that SSOAIC did not improve their results. There were regional variations in the use of SSOAIC which is used more frequently as secondary treatment in Europe compared to the USA and Japan. Ten centers identified cost is the major limiting factor for SSOAIC. CONCLUSION: SSOAIC is used in an increasing number of centers worldwide with regional variations. Centers with more experience in SSOAIC use it in more situations including other drugs than melphalan. The majority of the centers using this technique reported improved results and few complications.
Authors: Sandra Bracco; Sara Leonini; Sonia De Francesco; Samuele Cioni; Paola Gennari; Ignazio Maria Vallone; Pietro Piu; Daniela Galimberti; Daniele Giuseppe Romano; Mauro Caini; Mariacarla De Luca; Paolo Toti; Paolo Galluzzi; Theodora Hadjistilianou; Alfonso Cerase Journal: Br J Ophthalmol Date: 2013-07-12 Impact factor: 4.638
Authors: Jena J Steinle; Qiuhua Zhang; Karin Emmons Thompson; Jordan Toutounchian; C Ryan Yates; Carl Soderland; Fan Wang; Clinton F Stewart; Barrett G Haik; J Scott Williams; J Scott Jackson; Timothy D Mandrell; Dianna Johnson; Matthew W Wilson Journal: Invest Ophthalmol Vis Sci Date: 2012-04-30 Impact factor: 4.799
Authors: Carol L Shields; Carlos G Bianciotto; Pascal Jabbour; Gregory C Griffin; Aparna Ramasubramanian; Robert Rosenwasser; Jerry A Shields Journal: Arch Ophthalmol Date: 2011-06-13
Authors: Sotiria Palioura; Y Pierre Gobin; Scott E Brodie; Brian P Marr; Ira J Dunkel; David H Abramson Journal: Pediatr Blood Cancer Date: 2012-04-10 Impact factor: 3.167
Authors: Swathi Kaliki; Carol L Shields; Duangnate Rojanaporn; Saad Al-Dahmash; John P McLaughlin; Jerry A Shields; Ralph C Eagle Journal: Ophthalmology Date: 2013-02-08 Impact factor: 12.079
Authors: Christina Scelfo; Jasmine H Francis; Vikas Khetan; Thomas Jenkins; Brian Marr; David H Abramson; Carol L Shields; Jacob Pe'er; Francis Munier; Jesse Berry; J William Harbour; Andrey Yarovoy; Evandro Lucena; Timothy G Murray; Pooja Bhagia; Evelyn Paysse; Samuray Tuncer; Guillermo L Chantada; Annette C Moll; Tatiana Ushakova; David A Plager; Islamov Ziyovuddin; Carlos A Leal; Miguel A Materin; Xun-Da Ji; Jose W Cursino; Rodrigo Polania; Hayyam Kiratli; Charlotta All-Ericsson; Rejin Kebudi; Santosh G Honavar; Vicktoria Vishnevskia-Dai; Sidnel Epelman; Anthony B Daniels; Jeanie D Ling; Fousseyni Traore; Marco A Ramirez-Ortiz Journal: Int J Ophthalmol Date: 2017-06-18 Impact factor: 1.779
Authors: Nicolas Alessandro Yannuzzi; Jasmine H Francis; Brian P Marr; Irina Belinsky; Ira J Dunkel; Yves Pierre Gobin; David Harold Abramson Journal: JAMA Ophthalmol Date: 2015-09 Impact factor: 7.389
Authors: Debra L Friedman; Mark Krailo; Doojduen Villaluna; Dan Gombos; Bryan Langholz; Rima Jubran; Carol Shields; Linn Murphree; Joan O'Brien; Sandra Kessel; Carlos Rodriguez-Galindo; Murali Chintagumpala; Anna T Meadows Journal: Pediatr Blood Cancer Date: 2016-12-26 Impact factor: 3.167
Authors: Francis L Munier; Pascal Mosimann; Francesco Puccinelli; Marie-Claire Gaillard; Christina Stathopoulos; Susan Houghton; Ciara Bergin; Maja Beck-Popovic Journal: Br J Ophthalmol Date: 2016-12-07 Impact factor: 4.638
Authors: David H Abramson; Brian P Marr; Jasmine H Francis; Ira J Dunkel; Armida W M Fabius; Scott E Brodie; Ijah Mondesire-Crump; Y Pierre Gobin Journal: PLoS One Date: 2016-06-03 Impact factor: 3.240
Authors: David H Abramson; Armida W M Fabius; Reda Issa; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Y Pierre Gobin Journal: PLoS One Date: 2015-12-28 Impact factor: 3.240